Bruker Applied MS Unveils Strategic Innovations at ASMS 2025, Showcasing Advances in DART Technology for TDM and DoA Analysis and Launching timsMetabo™ for PFAS and Environmental Contaminant Detection
BILLERICA, Mass.--(BUSINESS WIRE)-- Bruker Corporation (NASDAQ: BRKR) today announced that its Applied Mass Spectrometry (Applied MS) division will present a powerful lineup of innovations at the 73rd American Society for Mass Spectrometry (ASMS) Conference, taking place June 1–5, 2025, in Baltimore, Maryland. These developments reflect Bruker's continued investment in applied markets, particularly in therapeutic drug monitoring (TDM), drugs of abuse (DoA) analysis and environmental analysis.
Bruker Applied MS will showcase two significant innovations: the integration of RECIPE's ClinMass ® and ClinDART ® assay kits with Bruker's EVOQ ® DART-TQ⁺ system for TDM and DoA applications, and the launch of the new timsMetabo™ platform for advanced small molecule analysis. These developments support Bruker's goal of delivering practical, high-performance solutions for routine analytical challenges.
Bruker's recent majority investment in RECIPE, a renowned manufacturer of diagnostic assays for small molecule analysis used with triple quadrupole mass spectrometers, marks an important step in expanding its capabilities in TDM and DoA analysis. Since the acquisition, Bruker and RECIPE have collaborated to verify the IVDR certified ClinMASS ® kits for use on the EVOQ DART-TQ⁺ system, initially targeting high-priority compound classes. They are not US-FDA approved, but single compounds as controls and calibrators may be a basis in LDT approaches. In parallel, the companies are preparing the launch of RECIPE's ClinDART ® kits, which are designed as high-throughput, chromatography-free assays for the EVOQ DART-TQ⁺ system. These kits enable rapid, cost-efficient analysis with highly reduced solvent consumption, ease of use and increased lab productivity. All ClinDART ® protocols are currently designated for Research Use Only (RUO).
Meanwhile, the newly introduced timsMetabo™ platform represents a leap forward in small molecule analysis. Built on Bruker's proprietary trapped ion mobility spectrometry (TIMS) and enhanced with Mobility Range Enhancement (MoRE) and the Athena Ion Processor (AIP), timsMetabo™ delivers high sensitivity and selectivity for PFAS detection. In early studies, timsMetabo™ identified 40% more low-mass molecules in water samples compared to previous-generation systems. This innovation supports both regulatory compliance and proactive environmental monitoring, with promising applications in toxicology and forensic science.
'The integration of RECIPE's assay expertise with Bruker's DART triple quad instrumentation is a significant advancement for therapeutic drug monitoring,' said Dr. Gernot Wolfram, Managing Director of RECIPE. 'It represents a promising concept with the potential to enable laboratories to adopt high-throughput, chromatography-free workflows that are efficient, robust, and more sustainable. These could dramatically enhance overall lab productivity and make mass spectrometry more accessible and impactful in routine clinical settings.'
'ASMS 2025 marks an important milestone for Bruker Applied MS,' said Jeffrey Zonderman, Senior Vice President of Bruker Applied Mass Spectrometry. 'With the launch of timsMetabo™ and the strategic integration of RECIPE, we are not only expanding our technology portfolio but also redefining what's possible in applied markets. These innovations reflect our commitment to solving real-world analytical challenges in TDM and environmental analysis.'
Looking ahead, Bruker Applied MS will continue to develop solutions for PFAS, forensic toxicology, and therapeutic drug monitoring. The timsMetabo™ platform is expected to support future applications involving low-mass drug metabolites and emerging contaminants, while RECIPE's assay pipeline will further enhance Bruker's applied market offerings.
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
38 minutes ago
- Business Upturn
Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering
New Taipei City, Taiwan, June 18, 2025 (GLOBE NEWSWIRE) — Jyong Biotech Ltd. (Nasdaq: MENS) (the 'Company'), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced the closing of its initial public offering (the 'Offering') of 2,666,667 ordinary shares (the 'Ordinary Shares') at a public offering price of $7.5 per share for aggregate gross proceeds of approximately $20 million, before deducting underwriting discounts and other offering expenses. The Ordinary Shares commenced trading on Nasdaq Global Market on June 17, 2025, under the ticker symbol 'MENS'. The Offering closed on June 18, 2025. The Company has granted the underwriters an option, exercisable within 45 days from the date of the final prospectus, to purchase up to an additional 400,000 Ordinary Shares at the public offering price, less underwriting discounts, to cover over-allotments, if any. The Company intends to use the net proceeds from the Offering for (i) funding the additional Phase III trials of MCS-2 (API-2) and the new drug application of MCS-2 (40%); (ii) funding earlier phase trials if the Company is unable to demonstrate comparability (25%); (iii) funding the Phase II trial of PCP (10%); (iv) funding the Phase I clinical trial of IC (5%), and (v) general corporate purposes (20%). The Offering was conducted on a firm commitment basis. Joseph Stone Capital, LLC acted as sole underwriter for the Offering (the 'Underwriter'). Sichenzia Ross Ference Carmel LLP acted as U.S. securities counsel to the Company, and VCL Law LLP acted as U.S. securities counsel to the Underwriter, in connection with the Offering. A registration statement on Form F-1 (File No. 333-277725) relating to the Offering, as amended, was previously filed with the U.S. Securities and Exchange Commission (the 'SEC') and was declared effective by the SEC on June 16, 2025. The Offering was made only by means of a prospectus. Copies of the prospectus related to the Offering may be obtained from Joseph Stone Capital, LLC by standard mail to Joseph Stone Capital, LLC, 585 Stewart Ave., Suite L60-C, Garden City, NY 11530, or via email at [email protected] or by telephone at +1 (888) 302-5548. In addition, a copy of the final prospectus relating to the Offering, dated June 16, 2025, can also be obtained via the SEC's website at Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Jyong Biotech Ltd. Headquartered in Taiwan, Jyong Biotech a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, MCS-2, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers' health needs and seeks to be a valuable business organization that is held in high esteem by the public. For more information, please visit: Forward-Looking Statement This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as 'may, 'will, 'intend,' 'should,' 'believe,' 'expect,' 'anticipate,' 'project,' 'estimate' or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, the Company's statements regarding the intended use of the proceeds from the Offering. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the 'Risk Factors' section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof. For more information, please contact: UnderwriterJoseph Stone Capital, LLC (888) 302-5548 [email protected]
Business Upturn
38 minutes ago
- Business Upturn
Willis launches Zest Insurance, a digital revolution for Australian SMEs
MELBOURNE, Australia, June 18, 2025 (GLOBE NEWSWIRE) — Willis, a WTW business (NASDAQ: WTW), today launches Zest Insurance, a cutting-edge digital insurance platform tailored specifically for small and medium enterprises (SMEs) in Australia. Zest Insurance represents a bold step forward in the digital transformation of SME insurance. It offers a seamless, fast and intuitive online experience backed by expert broker support. Designed to meet the evolving needs of modern business owners, Zest Insurance empowers SMEs to purchase, manage and renew their insurance policies entirely online. James Baum, Head of Pacific, WTW says: 'The launch of Zest Insurance comes at a pivotal time for the Australian SME market. With 97% of businesses having 20 or fewer employees, the platform is poised to serve a vast and growing segment of the market. Zest Insurance aims to bridge the gap between traditional insurance models and the digital expectations of modern SME owners.' Brent Lehmann, Head of Commercial & Affinity, Pacific at Willis, adds: 'SMEs are the backbone of the Australian economy, yet many still face outdated, complex processes when it comes to insurance. They increasingly demand convenience, speed and tailored insurance solutions. Zest Insurance is our answer to that challenge, bringing together digital convenience and trusted expertise in one powerful platform. It aims to make purchasing business insurance more straightforward for small business owners.' The Australian SME market, valued at over AUD 9 billion in gross written premium, has been slower to adopt digital insurance solutions compared to global counterparts. Zest Insurance aims to close that gap by offering: A fully digital customer journey – from insurance quote to bind, renewal, and policy management, all conducted online. – from insurance quote to bind, renewal, and policy management, all conducted online. Industry-specific insurance solutions – with one dedicated insurer per industry to ensure tailored coverage to protect businesses. – with one dedicated insurer per industry to ensure tailored coverage to protect businesses. User-friendly design – intuitive forms and interfaces built to enhance and simplify the customer experience. – intuitive forms and interfaces built to enhance and simplify the customer experience. Insurance broker support on demand – expert advice available when needed, ensuring confidence and clarity. Zest Insurance will be available initially to businesses in the administration and support services industry, including bookkeepers, payroll services, management and marketing consultants, market research firms and more, with plans to expand industry offerings in future phases. Zest Insurance policies for this first industry will be exclusively underwritten by Chubb, a world leader in insurance. James adds: 'We've built Zest Insurance to be more than just a platform. It's a new way of thinking about SME insurance. It's about simplicity, transparency and putting the customer first. Together, we're setting a new standard for SME insurance, starting in Australia.' For more information, visit: About WTW At WTW (NASDAQ: WTW), we provide data-driven, insight-led solutions in the areas of people, risk and capital. Leveraging the global view and local expertise of our colleagues serving 140 countries and markets, we help organizations sharpen their strategy, enhance organizational resilience, motivate their workforce and maximize performance. Working shoulder to shoulder with our clients, we uncover opportunities for sustainable success—and provide perspective that moves you. Learn more at Media contact Clara Goh: +65 6958 2542 [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Wire
41 minutes ago
- Business Wire
Gores Holdings X, Inc. Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing June 23, 2025
BOULDER, Colo.--(BUSINESS WIRE)--Gores Holdings X, Inc. (Nasdaq: GTENU) (the 'Company'), a blank check company sponsored by affiliates of The Gores Group, today announced that, commencing June 23, 2025, holders of the units sold in the Company's initial public offering of 35,880,000 units, which includes 4,680,000 units issued pursuant to the exercise by the underwriter of its overallotment option in full, may elect to separately trade the Class A ordinary shares and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Holders of units will need to have their brokers contact Computershare Trust Company, N.A., the Company's transfer agent, in order to separate the units into Class A ordinary shares and warrants. Those units not separated will continue to trade on the Nasdaq Global Market under the symbol 'GTENU,' and the Class A ordinary shares and warrants that are separated will trade on the Nasdaq Global Market under the symbols 'GTEN' and 'GTENW,' respectively. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering was made only by means of a prospectus, copies of which may be obtained from Santander US Capital Markets LLC, 437 Madison Avenue, New York, NY 10022, Attention: ECM Syndicate, by email at equity-syndicate@ or by telephone at 833-818-1602. About Gores Holdings X, Inc. Gores Holdings X, Inc. was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company's strategy is to identify, acquire and, after the initial business combination, to build a company in an industry or sector that complements the experience of its management team and can benefit from their operational expertise. Forward-Looking Statements This press release may include 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend' and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company's management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company's filings with the Securities and Exchange Commission ('SEC'). All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and preliminary prospectus for the Company's initial public offering filed with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
